Bradmer announces 2008 fourth quarter and fiscal year operational and financi... ( TSX: BMR TORONTO March 31 / Br...)

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

Date:3/31/2009

TSX: BMR

TORONTO, March 31 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer:

    -   Prepared and submitted the Company's drug manufacturing data package
        and clinical dossiers to the FDA;
    -   Initiated enrollment in the Phase III GLASS-ART clinical trial;
    -   Signed contracts with and activated an initial cohort of five U.S.
        clinical trial sites;
    -   Successfully released a second GMP drug substance batch for use in
        clinical trials and filed the related update with the FDA;
    -   Submitted new data from the previous Phase II trial indicating that
        the mean time to progression free survival was 77 weeks, which
        compares favorably with other published results in newly diagnosed
        GBM (Reardon et al.; 2008 Neuro-Oncology 10:845); and
    -   Sourced and validated commercial supplies of iodine-131 outside of
        the U.S. and Europe to prevent delays in raw material supply.

Subsequent to the financial year ended December 31, 2008, the Company commenced a strategic review of its operations, as more particularly described in press releases of the Company dated February 17, 2009 and March 5, 2009. Pursuant to the strategic review, the Company has closed its Phase III GLASS ART Trial to further patient enrollment due to unforeseen delays in site initiation and recruitment, the delayed ability to complete the 60 patient "run-in phase" in a timely manner, and the inability to raise further capital at this time.

The Company
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Bradmer implements cash conservation plan
2. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
3. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
4. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
5. Bradmer announces 2008 third quarter operational and financial results
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer receives FDA approval to proceed with Phase III clinical trial
8. Bradmer announces 2008 first quarter operational and financial results
9. Bradmer announces new additions to management team
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. Notice of Bradmer Pharmaceuticals Conference Call

Post Your Comments:

Bradmer announces 2008 fourth quarter and fiscal year operational and financi...( TSX: BMR TORONTO March 31 / Br...),Health